K-Dur Case: Reverse Payments Not “Established” Antitrust Violations – Judge
Executive Summary
Reverse payments from brand to generic companies in patent settlements are not "established" antitrust violations, an administrative law judge said in dismissing the Federal Trade Commission's antitrust case against Schering-Plough regarding K-Dur
You may also be interested in...
FTC Loses K-Dur Antitrust Case; Failure To Consider Schering Patent Cited
The Federal Trade Commission should consider the potential exclusionary scope of a brand-name drug company's patents when evaluating whether a settlement with a generic company is anticompetitive, a federal appeals court ruled March 8
FTC Loses K-Dur Antitrust Case; Failure To Consider Schering Patent Cited
The Federal Trade Commission should consider the potential exclusionary scope of a brand-name drug company's patents when evaluating whether a settlement with a generic company is anticompetitive, a federal appeals court ruled March 8
“Reverse” Payments Anti-Competitive In K-Dur Pact But Not All Cases – FTC
The Federal Trade Commission's ruling that the settlement between Schering-Plough and Upsher-Smith relating to K-Dur is anti-competitive stops short of defining all "reverse" payments as illegal